UNIV TX MD ANDERSON is a generic drug manufacturer focused on Oncology, Neurology.
UNIV TX MD ANDERSON's Key Drugs
UNIV TX MD ANDERSON's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
UNIV TX MD ANDERSON's Recent FDA Approvals
New NDA/BLA approvals for UNIV TX MD ANDERSON over the last two years — novel drugs only, excluding generics and label supplements.
UNIV TX MD ANDERSON's Therapeutic Areas
UNIV TX MD ANDERSON's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
UNIV TX MD ANDERSON's Top Competitors
UNIV TX MD ANDERSON's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
UNIV TX MD ANDERSON Pipeline Snapshot
Active clinical trials for UNIV TX MD ANDERSON across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2013-12-23
- Latest
- 2021-06-09
- Applications
- 4